Longeveron said its Phase 2b stem cell program in pediatric heart disease missed its primary endpoint, prompting the cash-strapped biotech to pursue cost-cutting and “review all options” for the business. The company’s response indicates the trial outcome will materially affect development commitments and near-term spending. The update reinforces how quickly late-stage signals can change resourcing in small biotechs, particularly those with limited operating runway. For stakeholders, the missed endpoint reduces the likelihood of rapid progression while increasing uncertainty around future trial design, potential partner interest, and timeline. Longeveron’s next steps will be watched for signs of asset reprioritization, licensing, or restructuring, as the biotech tries to stabilize finances while evaluating alternative strategic paths.